Analysts expect Nuo Therapeutics, Inc. to report revenue of 2.00 M for Q3 26, against a range of 1.80 M to 2.20 M. The most recent reported quarter, Q2 26, came in at 1.77 M, a 44.3% beat against the 1.23 M consensus.
| Metric | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.03 M | 1.10 M | 1.30 M | 1.77 M | - | - | - | - |
| High Estimate | - | 835,356.05 | 1.18 M | 1.28 M | 2.20 M | 2.28 M | 2.33 M | 2.53 M |
| Low Estimate | - | 771,872.15 | 1.09 M | 1.18 M | 1.80 M | 2.06 M | 1.97 M | 2.10 M |
| Consensus Estimate | - | 803,614.10 | 1.13 M | 1.23 M | 2.00 M | 2.17 M | 2.15 M | 2.31 M |
Analysts expect Nuo Therapeutics, Inc. to report earnings per share of -0.01 for Q3 26, against a range of -0.01 to -0.01. The most recent reported quarter, Q2 26, came in at -0.01 , in line with the -0.01 consensus.
| Metric | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.01 | -0.01 | -0.01 | -0.01 | - | - | - | - |
| High Estimate | - | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Low Estimate | - | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | - | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
Pull Wall Street consensus for Nuo Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AURX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AURX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AURX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();